| Total | Control | Overweight | Obese | P value |
---|---|---|---|---|---|
(BMI < 25 kg/m2) | (25 kg/m2 ≤ BMI < 30 kg/m2) | (BMI ≥ 30 kg/m2) | |||
Patients (n) | 523 | 407 | 98 | 18 | Â |
Age (median [IQR*1]) | 70.0 (62.5–77.0) | 71.0 (63.0–77.0) | 69.5 (61.5–75.0) | 67.5 (59.3–80.0) | 0.354 |
Sex, male (n) | 300 (57.4%) | 227 (55.8%) | 64 (65.3%) | 9 (50.0%) | 0.188 |
BMI*2 (kg/m2, median [IQR]) | 22.8 (20.3–24.8) | 21.7 (19.8–23.4) | 26.3 (25.6–27.3) | 32.4 (31.2–34.0) |  < 0.001 |
Cecal insertion time*3 (min, median [IQR]) | 5.5 (4.0–7.0) | 6.0 (4.0–7.5) | 5.0 (3.0–6.0) | 5.0 (4.0–5.25) | 0.086 |
Comorbidities (n) | |||||
 Hypertension | 236 (45.1%) | 174 (42.8%) | 53 (54.1%) | 9 (50.0%) | 0.118 |
 Diabetes | 66 (12.6%) | 46 (11.3%) | 18 (18.4%) | 2 (11.1%) | 0.164 |
 Cardiovascular disease | 17 (3.3%) | 14 (3.4%) | 2 (2.0%) | 1 (5.6%) | 0.668 |
 Cerebrovascular disease | 53 (10.1%) | 42 (11.5%) | 7 (7.1%) | 4 (22.2%) | 0.145 |
 Liver cirrhosis | 9 (1.7%) | 7 (1.7%) | 2 (2.0%) | 0 (0.0%) | 0.829 |
 Chronic renal failure | 15 (2.9%) | 14 (3.4%) | 1 (1.0%) | 0 (0.0%) | 0.331 |
 Respiratory disease*4 | 21 (4.0%) | 19 (4.7%) | 2 (2.0%) | 0 (0.0%) | 0.334 |
Antithrombotic medication (n) | 90 (17.2%) | 71 (17.4%) | 15 (15.3%) | 4 (22.2%) | 0.747 |
Lesion (n) | 586 | 458 | 108 | 20 | Â |
Location (n) | Â | 0.809 | |||
 Cecum | 84 (14.3%) | 66 (14.4%) | 13 (12.0%) | 5 (25.0%) |  |
 Ascending | 141 (24.1%) | 108 (23.6%) | 28 (25.9%) | 5 (25.0%) |  |
 Transverse | 131 (22.4%) | 100 (21.8%) | 26 (24.1%) | 5 (25.0%) |  |
 Descending | 47 (8.0%) | 35 (7.6%) | 11 (10.2%) | 1 (5.0%) |  |
 Sigmoid | 84 (14.3%) | 66 (14.4%) | 15 (13.9%) | 3 (15.0%) |  |
 Rectum | 99 (16.9%) | 83 (18.1%) | 15 (13.9%) | 1 (5.0%) |  |
Macroscopic type (n) | Â | 0.795 | |||
 Protruded | 99 (16.9%) | 78 (17.0%) | 17 (15.7%) | 4 (20.0%) |  |
 Elevated | 482 (82.2%) | 375 (81.9%) | 91 (84.3%) | 16 (80.0%) |  |
 Depressed | 5 (0.9%) | 5 (1.1%) | 0 (0.0%) | 0 (0.0%) |  |
Pathologycal diagnosis (n) | Â | 0.636 | |||
 Adenoma | 367 (62.6%) | 293 (64.0%) | 64 (59.3%) | 10 (50.0%) |  |
 Tis | 165 (28.2%) | 123 (26.9%) | 34 (31.5%) | 8 (40.0%) |  |
 T1 | 54 (9.2%) | 42 (9.2%) | 10 (9.3%) | 2 (10.0%) |  |